Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
NEW YORK — Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences and events: Stifel…
We haven't written up this one. Financial Post has the full story — the link below goes straight to it.
